SEO
undefined

undefined

SEO

Products

undefined

undefined

News

ProteLight Pharma Received the Approval for its First Human Clinical Study in Australia for the Antimicrobial Peptide PL-18 Suppository

ProteLight Pharma announced that its PL-18 suppository, the Chinese national category I new drug, a novel antimicrobial peptide, has passed ethical review by the Australian Therapeutic Goods Administration (TGA), and will start its first human clinical study in Australia.

隐藏域元素占位

ProteLight Pharma Innovative Drug Peceleganan Spray (Antimicrobial Peptide PL-5) Received FDA Approval for Phase II Clinical Trials in the United States

ProteLight Pharma announces the application of Peceleganan Spray (antimicrobial peptide PL-5) for Phase II clinical trial in the United States has been approved by the US Food and Health Administration (FDA).

隐藏域元素占位

Phase III Clinical Trial of the Innovative Drug-Antimicrobial Peptide PL-5 Spray Was Launched

On August 19, 2021, the “National Conference of Researchers on Phase III Clinical Trial of antimicrobial peptide PL-5 Spray in the treatment of secondary wound infection” was successfully held, marking that the clinical trial of the National “12th Five-Year Plan” and “13th Five-Year Plan” Mega-Projects for Innovative Drugs of China and the national category I innovative drug PL-5 officially will enter the home-stretch phase.

隐藏域元素占位

Love, Public Welfare and Warmth 2021-06-15 On June 3 and 4, 2021,

Protelight Pharma paid a visit to the Jiangyin fire brigade, Chengdong police station and Chengdong sanitation station, donated products to firefighters, police and sanitation workers who worked hard, and expressed thanks for their hard work!

隐藏域元素占位

Phase IIb Clinical Trial of Antimicrobial Peptide PL-5 Spray was Launched on 2020-07-26

On July 25, 2020, the “National Conference of Researchers on Phase IIb Clinical Trial of antimicrobial peptide PL-5 spray in the treatment of open wound infection" was successfully held in Shenzhen, marking that the National “12th Five-Year Plan” and “13th Five-Year Plan” Mega-Projects for Innovative Drugs of China and the national category I new drug PL-5 clinical trial officially entered the acceleration phase.

隐藏域元素占位

Notice of the general office of the State Health Commission on strengthening the management of diagnosis and treatment of chronic wounds (ulcers) on the body surface

In order to strengthen the management of diagnosis and treatment of chronic refractory wounds (ulcers), improve the level of diagnosis and treatment, ensure the safety of patients and the quality of diagnosis and treatment, and safeguard the health rights and interests of the people, the general office of the National Health Commission issued the notice on strengthening the management of diagnosis and treatment of chronic refractory wounds (ulcers) on December 2, 2019.

隐藏域元素占位

ProteLight Pharma was named the “Potential Unicorn Enterprise of Sunan National Innovation Park” 2019-11-18

On Nov. 4th, 2019, sponsored by the government of Jiangsu province, “the 7th Jiangsu Cooperation Conference between Industry and Research” was held in Nanjing. Over 400 experts from 150 universities and more than 2500 enterprises participated in this conference.

隐藏域元素占位

New Origin, New Journey – ProteLight Pharma Industry Base Formally Opens 2019-09-23

In the morning of September 20, 2019, leaders from Wuxi Government and guests from domestic and abroad arrived to attend the Grand Opening Ceremony of Phase I of ProteLight Pharma Industry Base.

隐藏域元素占位

ProteLignt Pharma Honored as “Wuxin Prospective Unicorn Enterprise in 2019”

On August 30, 2019, ProteLight Pharma was honored as the “Wuxin Prospective Unicorn Enterprise in 2019”.

隐藏域元素占位

The announcement of CFDA will effect a large collection of pharmaceutical companies

On April 28th, CFDA released “an announcement on cancelling to provide 36 items of documents (NO.34 file of 2019)”that will effect a large collection of pharmaceutical companies.

隐藏域元素占位